Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 (GemRIS) in muscle-invasive bladder cancer
NCT02722538Phase 1Completed
- Sponsor
- TARIS Biomedical
- Start
- May 2016
- Primary completion
- May 2019
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 2
01
Overview
Phase 1, open-label trial of gemcitabine-releasing intravesical system in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by TARIS Biomedical. Primary endpoint: Treatment Emergent Adverse Events. Started May 2016; status: completed.
02
Drugs
gemcitabine-releasing intravesical system
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT02722538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722538.